3zln: Difference between revisions
No edit summary |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Crystal structure of BCL-XL in complex with inhibitor (Compound 3)== | ==Crystal structure of BCL-XL in complex with inhibitor (Compound 3)== | ||
<StructureSection load='3zln' size='340' side='right' caption='[[3zln]], [[Resolution|resolution]] 2.29Å' scene=''> | <StructureSection load='3zln' size='340' side='right'caption='[[3zln]], [[Resolution|resolution]] 2.29Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[3zln]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[3zln]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3ZLN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3ZLN FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=H0Y:6-[(8E)-8-(1,3-BENZOTHIAZOL-2-YLHYDRAZINYLIDENE)-6,7-DIHYDRO-5H-NAPHTHALEN-2-YL]PYRIDINE-2-CARBOXYLIC+ACID'>H0Y</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.288Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=H0Y:6-[(8E)-8-(1,3-BENZOTHIAZOL-2-YLHYDRAZINYLIDENE)-6,7-DIHYDRO-5H-NAPHTHALEN-2-YL]PYRIDINE-2-CARBOXYLIC+ACID'>H0Y</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3zln FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3zln OCA], [https://pdbe.org/3zln PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3zln RCSB], [https://www.ebi.ac.uk/pdbsum/3zln PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3zln ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/B2CL1_HUMAN B2CL1_HUMAN] Potent inhibitor of cell death. Inhibits activation of caspases (By similarity). Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.<ref>PMID:19917720</ref> <ref>PMID:21840391</ref> Isoform Bcl-X(S) promotes apoptosis.<ref>PMID:19917720</ref> <ref>PMID:21840391</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 21: | Line 21: | ||
==See Also== | ==See Also== | ||
*[[B-cell lymphoma | *[[B-cell lymphoma proteins 3D structures|B-cell lymphoma proteins 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: | [[Category: Colman PM]] | ||
[[Category: | [[Category: Czabotar PE]] | ||
[[Category: | [[Category: Lessene GL]] | ||
[[Category: | [[Category: Smith BJ]] | ||